PDS Biotechnology (NASDAQ:PDSB), a clinical-stage immunotherapy company focused on innovative oncology and infectious disease solutions, released its second quarter results on August 13, 2025, for the ...
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer ...
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2025 Earnings Call Transcript March 30, 2026 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is $-0.13, expectations were $-0.2.
Fintel reports that on November 25, 2025, B. Riley Securities maintained coverage of PDS Biotechnology (NasdaqCM:PDSB) with a Buy recommendation. As of November 17, 2025, the average one-year price ...
View PDS Biotechnology Corp. PDSB stock quote prices, financial information, real-time forecasts, and company news from CNN.
This period saw the company reduce total operating expenses by 12.6% (GAAP), driven mainly by lower personnel and professional service fees. Research and development, or R&D, costs (GAAP) decreased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results